
The New York Genome Center (NYGC) is an independent, nonprofit academic research institute launched in 2011 that serves as a multi-institutional hub for genomic research. Leveraging our strengths in whole-genome sequencing and genomic analysis, our mission is the advancement of genomic science and its application to drive novel biomedical discoveries. NYGC’s areas of focus include the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative disease, and neuropsychiatric disease. In 2020, the NYGC also has directed its expertise to COVID-19 research.We are committed to prioritizing diversity, equity, and inclusion, which is fundamental to promoting greater collaboration, innovation, and discovery. Learn more about NYGC’s Commitment to Diversity, Equity, and Inclusion.

Human Genomics. 2021 July 13.
Coding and noncoding variants in EBF3 are involved in HADDS and simplex autism.

medRxiv. 2021 July 5.
Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study.

Seminars in Cancer Biology. 2021 June 25.